Vertaling van "Clinical immunology " (Engels → Nederlands) :

TERMINOLOGIE

autoimmunity | pathology of a disease in relation to immune system | clinical immunology | diseases caused by disorders of the immune system

https://ec.europa.eu/esco/port (...) (...) [HTML] [2017-12-31]

klinische immunologie

https://ec.europa.eu/esco/port (...) (...) [HTML] [2017-12-31]

https://ec.europa.eu/esco/port (...) [HTML] [2017-12-31]

diagnostic immunology methods | performances of diagnostic immunology | diagnostic immunology techniques | techniques of diagnostic immunology

https://ec.europa.eu/esco/port (...) (...) [HTML] [2017-12-31]

diagnostische immunologietechnieken

https://ec.europa.eu/esco/port (...) (...) [HTML] [2017-12-31]

https://ec.europa.eu/esco/port (...) [HTML] [2017-12-31]

Hospital-based outpatient immunology clinic

https://browser.ihtsdotools.or (...) (...) [HTML] [2018-01-01]

polikliniek immunologie in ziekenhuis

https://browser.ihtsdotools.or (...) (...) [HTML] [2018-01-01]

https://browser.ihtsdotools.or (...) [HTML] [2018-01-01]

immune tolerance | immunologic tolerance | immunological non-reactivity | immunological nonresponsiveness

http://iate.europa.eu/FindTerm (...) (...) [HTML] [2017-12-31]

immuuntolerantie

http://iate.europa.eu/FindTerm (...) (...) [HTML] [2017-12-31]

http://iate.europa.eu/FindTerm (...) [HTML] [2017-12-31]

http://iate.europa.eu/FindTerm (...) (...) [HTML] [2017-12-31]

pre-klinische proef | preklinische test

http://iate.europa.eu/FindTerm (...) (...) [HTML] [2017-12-31]

http://iate.europa.eu/FindTerm (...) [HTML] [2017-12-31]

give advanced clinical advice in physiotherapy | provide physiotherapy advanced clinical practice | provide advanced clinical practice for physiotherapy | provide advanced clinical practice in physiotherapy

https://ec.europa.eu/esco/port (...) (...) [HTML] [2017-12-31]

geavanceerde klinische praktijken in de fysiotherapie bieden | geavanceerde klinische praktijken in de kinesitherapie bieden

https://ec.europa.eu/esco/port (...) (...) [HTML] [2017-12-31]

https://ec.europa.eu/esco/port (...) [HTML] [2017-12-31]

immunologic memory | immunological memory

http://iate.europa.eu/FindTerm (...) (...) [HTML] [2017-12-31]

immunologisch geheugen

http://iate.europa.eu/FindTerm (...) (...) [HTML] [2017-12-31]

http://iate.europa.eu/FindTerm (...) [HTML] [2017-12-31]

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include sel ...[+++]

https://icd.who.int/browse10/2 (...) (...) [HTML] [2018-01-01]

Omschrijving: Dit blok omvat een grote verscheidenheid van stoornissen van verschillende ernst en klinische vorm, die evenwel alle aan het gebruik van een of meer psychoactieve middelen, al dan niet op medisch voorschrift, zijn toe te schrijven. De betrokken stof wordt aangegeven door middel van het derde teken van de code en het vierde teken specificeert de klinische toestand; deze codering dient, waar nodig, gebruikt te worden voor elk gespecificeerd middel, met dien verstande dat niet elk vierde teken van toepassing is op elke stof.

https://icd.who.int/browse10/2 (...) (...) [HTML] [2018-01-01]

https://terminologie.nictiz.nl (...) [HTML] [2018-01-01]

An adverse of effect of a drug that is not due to an immunologic or metabolic abnormality or to alterations in bioavailability or excretion. Joint AAAAI/ACAAI practice parameters-Drug intolerance 2010.

https://browser.ihtsdotools.or (...) (...) [HTML] [2018-01-01]

intolerantie voor drugs en/of geneesmiddelen

https://browser.ihtsdotools.or (...) (...) [HTML] [2018-01-01]

https://browser.ihtsdotools.or (...) [HTML] [2018-01-01]

An adverse effect of a food that is not due to an immunologic abnormality but rather to metabolic, toxic, pharmacologic or unknown processes. Joint AAAAI/ACAAI practice parameters-Food intolerance 2014.

https://browser.ihtsdotools.or (...) (...) [HTML] [2018-01-01]

voedingsintolerantie

https://browser.ihtsdotools.or (...) (...) [HTML] [2018-01-01]

https://browser.ihtsdotools.or (...) [HTML] [2018-01-01]

IN-CONTEXT TRANSLATIONS

More than 100 experts in clinical immunology, PID care, public health, and genetics, from EU/national ministries of health and agencies, academic centres, public health laboratories, industry, professional organisations and patient groups, were brought together to identify and develop public health strategies for PID.

https://eur-lex.europa.eu/lega (...) (...) [HTML] [2017-12-31]

Meer dan 100 deskundigen op het gebied van klinische immunologie, verzorging van patiënten met primaire immuundeficiënties (PID), volksgezondheid en genetica, alsmede deskundigen van de EU en nationale ministeries van gezondheid, agentschappen, universitaire centra, volksgezondheidslaboratoria, de industrie, beroepsorganisaties en patiëntengroepen werden samengebracht om volksgezondheidsstrategieën voor PID vast te stellen en te ontwikkelen.

https://eur-lex.europa.eu/lega (...) (...) [HTML] [2017-12-31]

https://eur-lex.europa.eu/lega (...) [HTML] [2017-12-31]

clinical proof of concept (i.e. trial) in immunological, respiratory, neurological and neurodegenerative diseases in just 5 years.

https://eur-lex.europa.eu/lega (...) (...) [HTML] [2014-05-05]

binnen vijf jaar de tweede klinische fase (d.w.z. proeven) voor immunologische, respiratorische, neurologische en neurodegeneratieve ziekten bereiken.

https://eur-lex.europa.eu/lega (...) (...) [HTML] [2014-05-05]

https://eur-lex.europa.eu/lega (...) [HTML] [2014-05-05]

ii) reduce the time to reach clinical proof of concept in medicine development, such as for immunological, respiratory, neurological and neurodegenerative diseases;

http://www.europarl.europa.eu/ (...) (...) [HTML] [2014-04-14]

ii) de tijd te bekorten die het kost om bij de ontwikkeling van geneesmiddelen, zoals voor immunologische, respiratorische, neurologische en neurodegeneratieve ziekten, de tweede klinische fase te bereiken;

http://www.europarl.europa.eu/ (...) (...) [HTML] [2014-04-14]

http://www.europarl.europa.eu/ (...) [HTML] [2014-04-14]

where possible , reduce the time to reach clinical proof of concept in medicine development, such as for cancer , immunological, respiratory, neurological and neurodegenerative diseases;

http://www.europarl.europa.eu/ (...) (...) [HTML] [2014-04-14]

indien mogelijk, de tijd te bekorten die het kost om bij de ontwikkeling van geneesmiddelen, zoals voor kanker of voor immunologische, respiratorische, neurologische en neurodegeneratieve ziekten, de tweede klinische fase te bereiken;

http://www.europarl.europa.eu/ (...) (...) [HTML] [2014-04-14]

http://www.europarl.europa.eu/ (...) [HTML] [2014-04-14]

For more results, go to https://pro.wordscope.com to translate your documents with Wordscope Pro!

where possible, reduce the time to reach clinical proof of concept in medicine development, such as for cancer, immunological, respiratory, neurological and neurodegenerative diseases;

http://eur-lex.europa.eu/legal (...) (...) [HTML] [2013-12-31]

indien mogelijk, de tijd te verkorten die het kost om bij de ontwikkeling van geneesmiddelen, zoals voor kanker of voor immunologische, respiratorische, neurologische en neurodegeneratieve ziekten, de tweede klinische fase te bereiken;

http://eur-lex.europa.eu/legal (...) (...) [HTML] [2013-12-31]

http://eur-lex.europa.eu/legal (...) [HTML] [2013-12-31]

More than 100 experts in clinical immunology, PID care, public health, and genetics, from EU/national ministries of health and agencies, academic centres, public health laboratories, industry, professional organisations and patient groups, were brought together to identify and develop public health strategies for PID.

http://eur-lex.europa.eu/legal (...) (...) [HTML] [2007-12-31]

Meer dan 100 deskundigen op het gebied van klinische immunologie, verzorging van patiënten met primaire immuundeficiënties (PID), volksgezondheid en genetica, alsmede deskundigen van de EU en nationale ministeries van gezondheid, agentschappen, universitaire centra, volksgezondheidslaboratoria, de industrie, beroepsorganisaties en patiëntengroepen werden samengebracht om volksgezondheidsstrategieën voor PID vast te stellen en te ontwikkelen.

http://eur-lex.europa.eu/legal (...) (...) [HTML] [2007-12-31]

http://eur-lex.europa.eu/legal (...) [HTML] [2007-12-31]

For gene and somatic cell therapy medicinal products, it is recognised that conventional requirements as laid down in Module 4 for non-clinical testing of medicinal products may not always be appropriate due to unique and diverse structural and biological properties of the products in question, including high degree of species specificity, subject specificity, immunological barriers and differences in pleiotropic responses.

https://eur-lex.europa.eu/lega (...) (...) [HTML] [2003-06-24]

Erkend wordt dat de gewone eisen van module 4 voor niet-klinisch onderzoek van geneesmiddelen niet altijd geschikt zijn voor geneesmiddelen voor gentherapie en somatische celtherapie, doordat deze geneesmiddelen unieke en uiteenlopende structurele en biologische eigenschappen hebben, zoals een hoge mate van soortspecificiteit, persoonspecificiteit, immunologische belemmeringen en verschillen in pleiotrope effecten.

https://eur-lex.europa.eu/lega (...) (...) [HTML] [2003-06-24]

https://eur-lex.europa.eu/lega (...) [HTML] [2003-06-24]

(1) Council Directive 81/851/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to veterinary medicinal products(3), Council Directive 81/852/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products(4), Council Directive 90/677/EEC of 13 December 1990 extending the scope of Directive 81/851/EEC on the approximation of the laws of the Member States relating to veterinary medicinal products and laying down additional provi ...[+++]

https://eur-lex.europa.eu/lega (...) (...) [HTML] [2001-11-05]

(1) Richtlijn 81/851/EEG van de Raad van 28 september 1981 betreffende de onderlinge aanpassing van de wetgevingen der lidstaten inzake geneesmiddelen voor diergeneeskundig gebruik(3), Richtlijn 81/852/EEG van de Raad van 28 september 1981 inzake de analytische, toxicologisch-farmacologische en klinische normen en voorschriften betreffende proeven op geneesmiddelen voor diergeneeskundig gebruik(4), Richtlijn 90/677/EEG van de Raad van 13 december 1990 tot uitbreiding van de werkingssfeer van Richtlijn 81/851/EEG betreffende de onderlinge aanpassing van de wetgevingen der lidstaten inzake geneesmiddelen voor diergeneeskundig gebruik, en h ...[+++]

https://eur-lex.europa.eu/lega (...) (...) [HTML] [2001-11-05]

https://eur-lex.europa.eu/lega (...) [HTML] [2001-11-05]

Council Directive 81/851/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to veterinary medicinal products , Council Directive 81/852/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products , Council Directive 90/677/EEC of 13 December 1990 extending the scope of Directive 81/851/EEC on the approximation of the laws of the Member States relating to veterinary medicinal products and laying down additional provisions for ...[+++]

https://eur-lex.europa.eu/lega (...) (...) [HTML] [2001-11-05]

Richtlijn 81/851/EEG van de Raad van 28 september 1981 betreffende de onderlinge aanpassing van de wetgevingen der lidstaten inzake geneesmiddelen voor diergeneeskundig gebruik , Richtlijn 81/852/EEG van de Raad van 28 september 1981 inzake de analytische, toxicologisch-farmacologische en klinische normen en voorschriften betreffende proeven op geneesmiddelen voor diergeneeskundig gebruik , Richtlijn 90/677/EEG van de Raad van 13 december 1990 tot uitbreiding van de werkingssfeer van Richtlijn 81/851/EEG betreffende de onderlinge aanpassing van de wetgevingen der lidstaten inzake geneesmiddelen voor diergeneeskundig gebruik, en houdende aanvullende bepali ...[+++]

https://eur-lex.europa.eu/lega (...) (...) [HTML] [2001-11-05]

https://eur-lex.europa.eu/lega (...) [HTML] [2001-11-05]

clinical proof of concept (i.e. trial) in immunological, respiratory, neurological and neurodegenerative diseases in just 5 years;

http://eur-lex.europa.eu/legal (...) (...) [HTML]

binnen vijf jaar de tweede klinische fase (d.w.z. proeven) voor immunologische, respiratorische, neurologische en neurodegeneratieve ziekten bereiken;

http://eur-lex.europa.eu/legal (...) (...) [HTML]

http://eur-lex.europa.eu/legal (...) [HTML]

Anderen hebben gezocht naar : chronic alcoholism dipsomania drug addiction delirium tremens hospital-based outpatient immunology clinic psychoactive substance abuse autoimmunity clinical immunology diagnostic immunology methods diagnostic immunology techniques disorder of personality and behaviour immune tolerance immunologic memory immunologic tolerance immunological memory immunological non-reactivity immunological nonresponsiveness jealousy non-clinical study paranoia performances of diagnostic immunology pre-clinical study pre-clinical test pre-clinical testing pre-clinical trial preclinical study preclinical test preclinical trial provide physiotherapy advanced clinical practice psychosis nos techniques of diagnostic immunology Clinical immunology

datacenter (1): www.wordscope.nl (v4.0.br)

'Clinical immunology' ->

Date index: 2022-03-20